Live Attenuated and Sub-Unit Vaccines Exploitation Against Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-COV2] | ||||
| International Journal of Medical Arts | ||||
| Article 4, Volume 5, Issue 4, April 2023, Page 3165-3176 PDF (1.14 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijma.2023.201871.1648 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohammed M. Kassab 
| ||||
| Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Giza, Egypt | ||||
| Abstract | ||||
| Background: Severe acute respiratory syndrome coronavirus 2 [SARS-COV2] is a serious infection nowadays. Infection is typically limited to the mucosal cells of the respiratory tract. At least 50% of infections are asymptomatic. Immunity is brief and reinfection occurs. Aim of the work: Live attenuated and sub-unit vaccines development against SARS-COV2 Patients and Methods: This was a screening experimental study. In our study, we designed sub-unit vaccine [A] for coherent and conserved Spike[S] protein and other coherent and conserved structural and non-structural proteins of the virus using bio-informatics applications software. Also, we prepared live attenuated vaccine of SARS-COV2 [B]. Results: Both vaccines [A and B] resulted in 97 and 96% efficacy, respectively during preclinical trials [animal testing] while showed 86 and 84% protection power during human clinical trials phases 1-2. They showed superior biological activity and fewer side effects than other standard vaccines such as Pfizer and Astrazenca vaccines. Their efficacy lasted from 2-3 months for vaccine A and 6-8 months for vaccine B. Conclusion: Both vaccines in our study were effective as prophylaxis against viral infection with SARS-COV2 and mutant forms of this virus. Booster doses are required to enhance immunity for both types of vaccines. | ||||
| Keywords | ||||
| Vaccine; Severe acute respiratory syndrome; Pneumonia; Droplets | ||||
|
Statistics Article View: 130 PDF Download: 99 |
||||
